

Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro- oesophageal junction adenocarcinoma

Information for the public
Published: 12 March 2025

www.nice.org.uk

Zolbetuximab (Vyloy) with fluoropyrimidine- and platinum-based chemotherapy is not normally available on the NHS for untreated, gastric or gastro-oesophageal junction adenocarcinoma in adults that is:

- locally advanced (has spread to nearby tissue), unresectable (cannot be surgically removed) or metastatic (has spread to other parts of the body), and
- claudin-18.2-positive and HER2-negative.

Your healthcare professional should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Information and support

The [NHS webpages on oesophageal cancer](#) or [stomach cancer](#) may be good places to find out more.

These organisations can give you advice and support:

- [OG Support](#), dave@ogsupport.uk or 07734 394263
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6876-3